QPPV.COM KNOWLEDGE ASSESSMENT

Spesolimab Classification, Mechanism and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Spesolimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of alternative explanations is particularly relevant when assessing a new pustular or psoriatic phenotype during spesolimab treatment?

Only medication overdose and dispensing error Infection-associated pustular eruption, bacterial superinfection, drug-triggered psoriasis, withdrawal or rebound, and unrelated systemic inflammatory disease Only hypersensitivity and injection-site reaction Only spontaneous reporting artefact

Question 2 of 10 Why should periodic safety evaluation distinguish the original development programme from evidence generated after broader clinical use?

Post-authorisation evidence is always less reliable than trial evidence Broader use may introduce new indications, ages, devices, switching patterns, combinations and exposure durations, changing denominators and signal opportunities Clinical-trial data should be discarded once marketing begins Only spontaneous reports can contribute to periodic benefit-risk evaluation

Question 3 of 10 Which stratification is most likely to prevent clinically important heterogeneity from being hidden in aggregate analyses?

Reporter profession only Indication, disease severity, treatment phase, duration, age, prior treatment, combination therapy and baseline risk Alphabetical order of preferred terms Country of report alone

Question 4 of 10 A liver enzyme elevation occurs during spesolimab treatment. Which assessment is most scientifically appropriate?

Attribute it to spesolimab because liver enzyme elevations are a mechanism-led concern Ignore it unless the patient has symptoms Review baseline and serial tests, imaging or functional assessment where appropriate, competing causes, concomitant medicines, persistence and recovery Treat the first abnormal value as definitive evidence of organ injury

Question 5 of 10 A QPPV is reviewing a serious neurological or vascular event reported during spesolimab treatment. Which follow-up is most appropriate?

Only the patient’s indication and the date of the last prescription Symptom onset, neurological examination, relevant MRI or CT findings, antithrombotic exposure, blood pressure, trauma and outcome Only whether the event was listed in the product information Only whether the patient recovered after discharge

Question 6 of 10 Which case narrative best supports a calibrated causality assessment?

It records only the event term and states that the mechanism proves causality It reconstructs treatment intent, exposure, onset, objective findings, treatment, outcome and competing causes, and explains the remaining uncertainty It focuses solely on the reporter’s opinion It records improvement after treatment interruption but omits concurrent therapies

Question 7 of 10 Which combination most accurately describes the pharmacovigilance significance of spesolimab’s classification?

It is a small-molecule anti-inflammatory whose safety can be assessed mainly through dose-related toxicity It is a humanised IgG1 monoclonal antibody and biological medicinal product, so target biology, immunogenicity and product quality attributes are relevant It is a vaccine-like product for which batch information is relevant but clinical context is not It is a nonspecific immunosuppressant whose adverse-event profile is independent of its molecular target

Question 8 of 10 What does it mean to say that a signal is a hypothesis requiring evaluation?

A signal is already sufficient to establish a causal relationship A signal indicates a pattern that warrants structured investigation but must be tested against alternatives, background rates, exposure data and data quality A signal should be ignored until a randomised trial confirms it A signal is equivalent to an individual case assessment

Question 9 of 10 Which operational measure best demonstrates that follow-up is effective rather than merely performed?

The case file contains a standard phrase stating that follow-up was requested The requested information was obtained, evaluated and incorporated into the seriousness, causality, expectedness or traceability assessment Every case received the same number of follow-up attempts Follow-up was closed after the first unanswered request regardless of the information needed

Question 10 of 10 A case contains only the term rash after spesolimab administration. What is the principal pharmacovigilance limitation?

The term is too specific to be clinically useful The term cannot distinguish administration reaction, disease activity, drug-triggered psoriasis, infection-associated eruption or another cause The term automatically indicates a quality defect The term proves that the event was mild

Spesolimab Classification, Mechanism and Pharmacovigilance Knowledge Assessment

Cookie Settings